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It has been established in the past few decades that the vascular endo-
thelium, the monolayer of cells covering the inner surface of the
vessel wall, functions as a master regulator to maintain the physio-
logical integrity of vascular function and structure by actively releasing
numerous vasoactive hormones that control smooth muscle cell con-
traction and proliferation and inﬂammatory cell adhesion and inﬁltra-
tion into the vascular wall.1 Endothelial dysfunction, which usually
refers to a decrease in bioavailability of the vasoprotective nitric
oxide (NO) from endothelial NO synthase (eNOS) in the presence
of cardiovascular risk factors such as hypertension, hypercholesterol-
aemia, hyperglycaemia, and ageing, includes also other functional
alterations due to pro-inﬂammatory, pro-coagulant, and pro-
thrombotic properties and plays an important role in promoting ath-
erosclerotic vascular disease.1 This endothelium-centric ‘inside-out’
injury paradigm of pathogenesis of vascular disease was initially pro-
posed by Ross and Glomset in 1970s2 and has led to the important
concept that modiﬁcation to preserve the luminal endothelial function
would protect blood vessels from the development of vascular dis-
eases. Indeed, emerging research from studies of recent years demon-
strates that mice with endothelium-speciﬁc inhibition of functional
nuclear factor-kB (NF-kB) signalling, the major transcription factor
in mediating inﬂammation,3 are protected from atherosclerosis,4
hypertension-induced renal damage,5 septic shock, and septic endo-
thelial dysfunction.6 Most recently, Katagiri’s group showed that
mice with endothelium-speciﬁc blockade—by transgenic expression
of dominant-negative IkBa under the control of the Tie2 promotor/
enhancer (E-DNIkB mice)—are also protected from the development
of insulin resistance associated with obesity and ageing, and the mice
have a prolonged lifespan.7 The same group in the current issue of
Cardiovascular Research8 now further demonstrates that these mice
with endothelium-speciﬁc inhibition of NF-kB signalling show attenu-
ated intimal hyperplasia and aneurysm formation most likely through
inhibition of vascular inﬂammation and matrix metalloproteinases
(MMPs).
What are the major, special advances of this study compared with
the previous studies? Unlike the conventional experimental approach,
which induces intimal hyperplasia in arteries by damaging the endo-
thelial layer through angioplasty, the authors introduce vascular
injury from the adventitial side of the femoral artery in mice by
placing a perivascular cuff surrounding the blood vessel. This is a
typical vascular remodelling model in which injury initially occurs in
the adventitia instead the endothelial layer. In addition, the aortic an-
eurysmal mouse model—hypercholesterolaemic, atherosclerosis-
prone, ApoE-deﬁcient mice with or without E-DNIkB, and treated
with angiotensin II to facilitate vascular wall inﬂammation, a well-
studied vascular remodelling model mainly associated with media
and adventitial degeneration9—was also used to investigate the cross-
talk between the endothelium and the media/adventitia. The term
‘vascular remodelling’ is considered a process that mainly occurs in
adventitia and media, where chronic inﬂammation plays a key role.10
It refers to a spatial reorganization of the vascular wall components
resulting in geometric changes. Vascular remodelling can be either
inward (constrictive), leading to lumen narrowing, or outward (expan-
sive), leading to vascular lumen enlargement, and it is the crucial
process responsible for de novo atherosclerosis, restenosis after cor-
onary intervention, and aortic aneurysm formation.11,12 Although
the cellular and molecular mechanisms that control vascular remodel-
ling are poorly understood, it has been suggested that myoﬁbroblast
proliferation, smooth muscle cell phenotype transformation, cell
apoptosis, inﬂammatory cell inﬁltration, and secretion of inﬂammatory
cytokines and MMPs, which modify extracellular matrix composition,
act in concert to determine the pathological vascular remodelling
process that leads to either vascular (re)stenosis or aneurysm forma-
tion.12 The results of this study by Katagiri’s group are of particular
relevance towards understanding the regulatory mechanisms of vascu-
lar remodelling and indicate that the vascular endothelium is capable
of sensing injury from adventitia through NF-kB signalling, participat-
ing in pathological vascular remodelling.
However, this concept remains to be fully proved and the following
critical questions must be adequately addressed: (i) What are the
initial signals generated from adventitial injury and from which cells
do the signals derive? (ii) How are these signals transmitted to the
endothelial cells and how is NF-kB signalling activated in these cells?
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(iii) What is the molecular mechanism of the NF-kB signalling blockade
in endothelial cells responsible for the inhibition of pathological vascu-
lar remodelling and associated inﬂammation? Is this attributable to
improved eNOS function, since eNOS expression is enhanced in the
E-DNIkB mice and eNOS gene deﬁciency abolishes the effects of
decreased systemic blood pressure and increased muscle blood ﬂow
in aged E-DNIkB mice7 and functional intact eNOS is important for in-
hibition of vascular inﬂammation and ageing?13 (iv) Is there a vicious
circle between adventitial ‘outside-in’ injury and endothelial ‘inside-out’
injury? Although the answer is likely ‘yes’, it has to be proved. (v) Finally,
the most critical question that remains unanswered is whether the in-
hibitory effects of vascular inﬂammation and pathological remodelling
observed in this study are attributable, at least in part, to the functional
preservation of the endothelial cells of the adventitial vasa vasorum in
the E-DNIkB mice, since the vasa vasorum has been suggested to be an
important player in mediating vascular wall inﬂammation and remodel-
ling.14 Answering these questions will further strengthen and prove the
currently developed vascular ‘outside-in’ injury concept and will also
have an important impact on understanding the mechanisms of patho-
genesis of atherosclerosis and vascular complications associated with
risk factors such as obesity and ageing in which perivascular tissue dys-
function in vascular diseases is implicated.15
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